Abstract
Ceftazidime/avibactam comprises the broad-spectrum cephalosporin ceftazidime and the non-β-lactam β-lactamase inhibitor avibactam. This phase 3, randomised, double-blind study (NCT01726023) assessed the efficacy and safety of ceftazidime/avibactam plus metronidazole compared with meropenem in patients with complicated intra-abdominal infection (cIAI) in Asian countries. Subjects aged 18–90 years and hospitalised with cIAI requiring surgical intervention were randomised 1:1 to receive every 8 h either: ceftazidime/avibactam (2000/500 mg, 2-h infusion) followed by metronidazole (500 mg, 60-min infusion); or meropenem (1000 mg, 30-min infusion). Non-inferiority of ceftazidime/avibactam plus metronidazole to meropenem was concluded if the lower limit of the 95% confidence interval (CI) for the between-group difference in clinical cure rate was greater than −12.5% at the test-of-cure (TOC) visit (28–35 days after randomisation) in the clinically evaluable (CE) population. Safety was also evaluated. Of 441 subjects randomised, 432 received at least one dose of study medication (ceftazidime/avibactam plus metronidazole, n = 215; meropenem, n = 217). In the CE population at the TOC visit, non-inferiority of ceftazidime/avibactam plus metronidazole to meropenem was demonstrated, with clinical cure reported for 93.8% (166/177) and 94.0% (173/184) of subjects, respectively (between-group difference, −0.2, 95% CI −5.53 to 4.97). The clinical cure rate with ceftazidime/avibactam plus metronidazole was comparable in subjects with ceftazidime-non-susceptible and ceftazidime-susceptible isolates (95.7% vs. 92.1%, respectively). Adverse events were similar between the study groups. Ceftazidime/avibactam plus metronidazole was non-inferior to meropenem in the treatment of cIAIs in Asian populations and was effective against ceftazidime-non-susceptible pathogens. No new safety concerns were identified.
| Original language | English |
|---|---|
| Pages (from-to) | 579-588 |
| Number of pages | 10 |
| Journal | International Journal of Antimicrobial Agents |
| Volume | 49 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2017 May 1 |
Bibliographical note
Funding Information:The authors would like to thank the patients, their families and all investigators involved in this study. The authors also thank Niwat Montreewasuwat for involvement in data collection and analysis. Medical writing support, including assisting authors with the development of the outline and initial draft, incorporation of comments, fact checking, referencing, figure preparation, proofreading and submission, was provided by Catherine Savage, PhD, and editorial support, including fact checking and proofreading was provided by Valerie Moss, PhD, CMPP, both of Prime (Knutsford, UK) supported by AstraZeneca and Pfizer according to Good Publication Practice guidelines (http://annals.org/aim/article/2424869/good-publication-practice-communicating-company-sponsored-medical-research-gpp3). Ceftazidime/avibactam is being developed by Pfizer and Allergan Inc. The study sponsor (AstraZeneca) managed data collection and analysed the data. All authors had full access to all trial data and take responsibility for the integrity of the data and the accuracy of the data analysis.
Publisher Copyright:
© 2017 The Authors
Keywords
- Asia
- Ceftazidime/avibactam
- Complicated intra-abdominal infection
- Efficacy
- Phase 3
- Safety
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
- Pharmacology (medical)
